Generate Biomedicines(GENB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

GENB Generate Biomedicines

Trading 03-26 10:46:08 EDT

12.47

+0.64

+5.41%

High12.64	Low11.82	Vol60.71K
Open11.98	D1 Closing11.83	Amplitude6.93%
Mkt Cap1.59B	Tradable Cap311.75M	Total Shares127.45M
T/O754.37K	T/O Rate0.24%	Tradable Shares25.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"GENB","market":"US","secType":"STK","nameCN":"Generate Biomedicines","latestPrice":12.47,"timestamp":1774536285325,"preClose":11.83,"halted":0,"volume":60708,"delay":0,"changeRate":0.05409974640743876,"floatShares":25000000,"shares":127450200,"eps":-1.958,"marketStatus":"Trading","change":0.64,"latestTime":"03-26 10:46:08 EDT","open":11.98,"high":12.64,"low":11.8205,"amount":754373.3920799999,"amplitude":0.069273,"askPrice":12.61,"askSize":301,"bidPrice":12.32,"bidSize":125,"shortable":3,"etf":0,"ttmEps":-1.958,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1774555200000},"marketStatusCode":2,"adr":0,"listingDate":1772168400000,"exchange":"NASDAQ","adjPreClose":11.83,"preHourTrading":{"tag":"盘前","latestPrice":12.15,"preClose":11.83,"latestTime":"08:45 EDT","volume":116,"amount":1391.209924,"timestamp":1774529121628,"change":0.32,"changeRate":0.02705,"amplitude":0.06847},"postHourTrading":{"tag":"盘后","latestPrice":11.83,"preClose":11.83,"latestTime":"19:54 EDT","volume":345,"amount":4082.2,"timestamp":1774482892453,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.702946},"requestUrl":"/m/hq/s/GENB","defaultTab":"news","newsList":[{"id":"2622006872","title":"BUZZ-Morgan Stanley bullish on Generate Biomedicines, cites strength of lead asthma drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2622006872","media":"Reuters","labels":["shareholding","productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622006872?lang=en_us&edition=fundamental","pubTime":"2026-03-26 01:52","pubTimestamp":1774461124,"startTime":"0","endTime":"0","summary":"BUZZ-Morgan Stanley bullish on Generate Biomedicines, cites strength of lead asthma drug** Morgan Stanley initiates drug developer Generate Biomedicines GENB.O with an \"overweight\" rating as research quiet period ends** Company secured a valuation of nearly $1.91 bln at open after its debut on the Nasdaq late last month** Brokerage cites, \"we see GENB's lead asset, GB-0895, as having best-in-class potential vs. blockbuster generating commercial benchmarks\"** GB-0895 is GENB's lead product to treat severe asthma which is being tested in a late-stage trial ** \"We believe GB-0895 has credible best-in-class potential in severe asthma by improving on a validated mechanism rather than reinventing the biology\"- MS** Goldman Sachs, Morgan Stanley, Piper Sandler, Guggenheim Securities and Cantor were the underwriters for GENB's offering** As of last close, stock down 24% since its debut on Feb. 27  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nL4N40D1S9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4127","BK4139","LU0053671581.USD","GENB","PIPR"],"gpt_icon":0},{"id":"2622077173","title":"Generate Biomedicines: Differentiated AI-Driven Protein Platform with GB-0895 Asthma Lead and Emerging Oncology Upside Justifies Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2622077173","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622077173?lang=en_us&edition=fundamental","pubTime":"2026-03-25 22:45","pubTimestamp":1774449917,"startTime":"0","endTime":"0","summary":"Salveen Richter, an analyst from Goldman Sachs, has initiated a new Buy rating on Generate Biomedicines, Inc. (GENB). Salveen Richter has given his...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/generate-biomedicines-differentiated-ai-driven-protein-platform-with-gb-0895-asthma-lead-and-emerging-oncology-upside-justifies-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/generate-biomedicines-differentiated-ai-driven-protein-platform-with-gb-0895-asthma-lead-and-emerging-oncology-upside-justifies-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CHAT","GENB","AIPO","AGIX"],"gpt_icon":0},{"id":"2622023931","title":"U.S. RESEARCH ROUNDUP-Amazon, Diamondback Energy, Matador Resources","url":"https://stock-news.laohu8.com/highlight/detail?id=2622023931","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622023931?lang=en_us&edition=fundamental","pubTime":"2026-03-25 16:01","pubTimestamp":1774425680,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Amazon, Diamondback Energy, Matador ResourcesMarch 25 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies on Wedn","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nL8N40D0JI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CDE","AMZN","BWXT","AIR","DK","CEGX","BCAX","DINO","FRPT","AZYY","BXP","CVI","AMZP","CEG","FIGG","ELVN","BTM","BP","AARD","FANG","KBH","AFG","GLW","INSM","AMZD","BRZE","ABSI","BPH","AMZU","FIG","AVAH","ACAD","AVTX","EVGO","APEI","CVX","ARE","BZAI","CALM","HAL","CNM","HD","GENB","USAW.SI","MTDR","BAM","DG","ADUS","ESE"],"gpt_icon":1},{"id":"2621706775","title":"Generate Biomedicines Initiated at Overweight by Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2621706775","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621706775?lang=en_us&edition=fundamental","pubTime":"2026-03-24 21:02","pubTimestamp":1774357320,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GENB/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 24, 2026 09:02 ET (13:02 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GENB"],"gpt_icon":0},{"id":"2621205062","title":"Generate Biomedicines Inc : Morgan Stanley Initiates Coverage With Overweight Rating; Price Target $20","url":"https://stock-news.laohu8.com/highlight/detail?id=2621205062","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621205062?lang=en_us&edition=fundamental","pubTime":"2026-03-24 20:44","pubTimestamp":1774356269,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nFWN40C0T1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GENB"],"gpt_icon":0},{"id":"2621061288","title":"Cantor Fitzgerald Initiates Coverage on Generate Biomedicines With Overweight Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2621061288","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621061288?lang=en_us&edition=fundamental","pubTime":"2026-03-24 19:50","pubTimestamp":1774353049,"startTime":"0","endTime":"0","summary":"Cantor Fitzgerald Initiates Coverage on Generate Biomedicines With Overweight Rating","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GENB"],"gpt_icon":0},{"id":"2621061159","title":"Generate Biomedicines Initiated at Buy by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2621061159","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621061159?lang=en_us&edition=fundamental","pubTime":"2026-03-24 19:46","pubTimestamp":1774352760,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GENB/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 24, 2026 07:46 ET (11:46 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GENB","BK4139"],"gpt_icon":0},{"id":"2621063010","title":"Morgan Stanley Initiates Generate Biomedicines at Overweight With $20 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2621063010","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621063010?lang=en_us&edition=fundamental","pubTime":"2026-03-24 18:17","pubTimestamp":1774347431,"startTime":"0","endTime":"0","summary":"Morgan Stanley Initiates Generate Biomedicines at Overweight With $20 Price Target","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GENB"],"gpt_icon":0},{"id":"2621068889","title":"Generate Biomedicines initiated with a Buy at Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2621068889","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621068889?lang=en_us&edition=fundamental","pubTime":"2026-03-24 17:15","pubTimestamp":1774343742,"startTime":"0","endTime":"0","summary":"Guggenheim initiated coverage of Generate Biomedicines (GENB) with a Buy rating and $30 price target The firm has “high conviction in multi-blockbu...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/generate-biomedicines-initiated-with-a-buy-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/generate-biomedicines-initiated-with-a-buy-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","GENB"],"gpt_icon":0},{"id":"2621050714","title":"Generate Biomedicines initiated with an Overweight at Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2621050714","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621050714?lang=en_us&edition=fundamental","pubTime":"2026-03-24 17:00","pubTimestamp":1774342831,"startTime":"0","endTime":"0","summary":"Piper Sandler analyst Edward Tenthoff initiated coverage of Generate Biomedicines (GENB) with an Overweight rating and $24 price target The company...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/generate-biomedicines-initiated-with-an-overweight-at-piper-sandler-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/generate-biomedicines-initiated-with-an-overweight-at-piper-sandler-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GENB"],"gpt_icon":0},{"id":"2621575470","title":"Generate Biomedicines initiated with a Buy at Goldman Sachs","url":"https://stock-news.laohu8.com/highlight/detail?id=2621575470","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621575470?lang=en_us&edition=fundamental","pubTime":"2026-03-24 16:35","pubTimestamp":1774341311,"startTime":"0","endTime":"0","summary":"Goldman Sachs initiated coverage of Generate Biomedicines (GENB) with a Buy rating and $26 price target The company integrates generative AI models...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/generate-biomedicines-initiated-with-a-buy-at-goldman-sachs-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/generate-biomedicines-initiated-with-a-buy-at-goldman-sachs-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0345770993.USD","AIYY","BK4543","IE0002270589.USD","LU1868836914.USD","LU2237443978.SGD","LU2237443465.HKD","LU2750360997.AUD","LU1668664300.SGD","LU2471134952.CNY","LU2237443622.USD","LU0061475181.USD","LU1791807156.HKD","LU2471134523.USD","BK4587","IE00BSNM7G36.USD","IE0034235188.USD","LU1868836591.USD","LU2265009873.SGD","IE0004086264.USD","LU1868837300.USD","LU2237443895.HKD","BK4127","BK4139","BK4023","IE00B19Z3581.USD","LU0742534661.SGD","LU1868836757.USD","LU1894683348.USD","GENB","AI","BK4516","LU2237443382.USD","BK4550","GSX","LU0345770308.USD","IE00B19Z3B42.SGD","BK4585","BK4588","LU0251142724.SGD","LU2471134796.USD","LU0251131958.USD","IE0004091025.USD","LU2750360641.GBP","LU2237438978.USD","LU0106831901.USD","BK4551","BK4504","BK4528","LU2471134879.HKD"],"gpt_icon":0},{"id":"2621000051","title":"Generate Biomedicines Inc : Piper Sandler Initiates Coverage With Overweight Rating; Price Target $24","url":"https://stock-news.laohu8.com/highlight/detail?id=2621000051","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621000051?lang=en_us&edition=fundamental","pubTime":"2026-03-24 15:43","pubTimestamp":1774338190,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nFWN40B0RB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GENB","BK4139"],"gpt_icon":0},{"id":"2621012051","title":"U.S. RESEARCH ROUNDUP-Apogee Therapeutics, Insmed, Sunoco","url":"https://stock-news.laohu8.com/highlight/detail?id=2621012051","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621012051?lang=en_us&edition=fundamental","pubTime":"2026-03-24 15:39","pubTimestamp":1774337945,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Apogee Therapeutics, Insmed, SunocoMarch 24 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Apogee","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nL4N40C0IK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BRX","ACDC","SMCI","DAR","LGND","SMCL","LU0354030511.USD","BK4515","NCNO","CXW","INSM","SMCC","SMCZ","CF","XNCR","VTRS","SMCX","VZ","NYT","CCL","GENB","KRYS","SUN","LU0496365809.HKD","STRO","RL","FRT","SMYY","BK4189","SRZN","APGE","T","ECL","WEC","MKC","BK4165","SPG","SMCY","DXCM","APA","RLMD","LW","PFE","KMI","TSN","BK4504","BG","LU0690374961.EUR","REG","ADM"],"gpt_icon":0},{"id":"2617538936","title":"Generate Biomedicines CEO Michael Nally Acquires Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2617538936","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617538936?lang=en_us&edition=fundamental","pubTime":"2026-03-07 05:56","pubTimestamp":1772834209,"startTime":"0","endTime":"0","summary":"Michael Nally, chief executive officer and director of Generate Biomedicines Inc., reported acquiring 20,000 shares of the company’s common stock. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Generate Biomedicines Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 06, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nNDL7rR47K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Generate Biomedicines CEO Michael Nally Acquires Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GENB"],"gpt_icon":0},{"id":"2616636213","title":"Generate Biomedicines Director Jane L Mendillo Acquires Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2616636213","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616636213?lang=en_us&edition=fundamental","pubTime":"2026-03-03 06:48","pubTimestamp":1772491686,"startTime":"0","endTime":"0","summary":"Jane L Mendillo, a director of Generate Biomedicines Inc., reported an acquisition of 1,500 common shares. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Generate Biomedicines Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 02, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nNDL3FZcFV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GENB"],"gpt_icon":0},{"id":"2616362984","title":"Noubar Afeyan, Director, Acquires Generate Biomedicines Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2616362984","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616362984?lang=en_us&edition=fundamental","pubTime":"2026-03-03 06:43","pubTimestamp":1772491420,"startTime":"0","endTime":"0","summary":"Noubar Afeyan, a director and 10% owner of Generate Biomedicines Inc., reported the acquisition of common shares. The filing also lists reporting beneficial owners including Flagship VentureLabs VI LLC, Flagship Pioneering Fund VI, L.P., Flagship Pioneering Fund VII, L.P., Nutritional Health LTP Fund, L.P., and other reporting beneficial owners. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Generate Biomedicines Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 02, 2026, and is solely responsible for the information contain","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nNDL8qZfyL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Noubar Afeyan, Director, Acquires Generate Biomedicines Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GENB"],"gpt_icon":0},{"id":"2616364281","title":"Generate Biomedicines Adopts Amended and Restated Bylaws","url":"https://stock-news.laohu8.com/highlight/detail?id=2616364281","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616364281?lang=en_us&edition=fundamental","pubTime":"2026-03-03 06:22","pubTimestamp":1772490160,"startTime":"0","endTime":"0","summary":"Generate Biomedicines Inc. announced amended and restated bylaws that took effect with the effectiveness of its IPO registration statement. The changes establish procedures for stockholders to take formal actions at stockholder meetings, add an advance notice process for stockholder proposals and director nominations at annual meetings, and update the bylaws to align with the company’s amended and restated certificate of incorporation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Generate Biomedicines Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 02, 2026, and is solely res","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nNDL8gq2lY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GENB"],"gpt_icon":0},{"id":"2616735468","title":"Opening Day: Generate Biomedicines makes public debut","url":"https://stock-news.laohu8.com/highlight/detail?id=2616735468","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616735468?lang=en_us&edition=fundamental","pubTime":"2026-03-03 00:30","pubTimestamp":1772469040,"startTime":"0","endTime":"0","summary":"Generate Biomedicines made its public debut last week. The clinical‑stage company, which positions itself as a pioneer in AI‑driven drug design and...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/opening-day-generate-biomedicines-makes-public-debut-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/opening-day-generate-biomedicines-makes-public-debut-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4528","AIYY","BK4023","BK4551","BK4588","GENB","BK4543","BK4587","BK4585"],"gpt_icon":0},{"id":"2614143869","title":"Generate Biomedicines Shares Fall After Nasdaq Debut","url":"https://stock-news.laohu8.com/highlight/detail?id=2614143869","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614143869?lang=en_us&edition=fundamental","pubTime":"2026-02-28 02:22","pubTimestamp":1772216575,"startTime":"0","endTime":"0","summary":"Generate Biomedicines (GENB) shares fell 15% to $13.67 in their Nasdaq debut on Friday after the company priced its initial public offering of 25 million shares at $16 each.The stock opened at $15 and fell as low as $13.47.Price: 13.67, Change: -2.33, Percent Change: -14.56","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GENB","NQmain"],"gpt_icon":0},{"id":"1192265905","title":"Stock Track | Generate Biomedicines Plummets 6.25% Intraday as Stock Debuts Below IPO Price","url":"https://stock-news.laohu8.com/highlight/detail?id=1192265905","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192265905?lang=en_us&edition=fundamental","pubTime":"2026-02-28 02:09","pubTimestamp":1772215784,"startTime":"0","endTime":"0","summary":"Generate Biomedicines (GENB) saw its stock plummet 6.25% during intraday trading on Friday, following its initial public offering.The decline came as the company's shares opened at $15 in their...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["GENB"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.generatebiomedicines.com","stockEarnings":[{"period":"1week","weight":0.0017},{"period":"1month","weight":-0.2606},{"period":"ytd","weight":-0.2606}],"compareEarnings":[{"period":"1week","weight":-0.007},{"period":"1month","weight":-0.0375},{"period":"3month","weight":-0.0486},{"period":"6month","weight":-0.0076},{"period":"1year","weight":0.1414},{"period":"ytd","weight":-0.0368}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"exchange":"NASDAQ","name":"Generate Biomedicines","nameEN":"Generate Biomedicines"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Generate Biomedicines(GENB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Generate Biomedicines(GENB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Generate Biomedicines,GENB,Generate Biomedicines股票,Generate Biomedicines股票老虎,Generate Biomedicines股票老虎国际,Generate Biomedicines行情,Generate Biomedicines股票行情,Generate Biomedicines股价,Generate Biomedicines股市,Generate Biomedicines股票价格,Generate Biomedicines股票交易,Generate Biomedicines股票购买,Generate Biomedicines股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Generate Biomedicines(GENB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Generate Biomedicines(GENB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}